Home |
About |
Publications |
Science |
Contact |
Computational Chemistry ResourceMolecular Design Consultancy for Drug Discovery |
Hit Finding |
Hit to Lead |
Lead Optimisation |
IsoProbes: Molecular Fragment Docking Commercial Compound Selections Virtual library DesignBiologcally Active Chemical Spaces |
Potency OptimisationModel ImprovementSynthetic LibrariesPatentability | MetabolismToxPharmacoKinetics |
Data Analysis |
Structure Based Design |
Med Chem Project Support |
Database/Literature/Patent Searching Analysis of SAR Shape, Pharmacophore and Property ProfilingSelection of Commercial Screening Sets |
Visualisation and overlay of 3D StructuresSequence Comparison3D Homology ModelsActive Site MappingProtein DynamicsFragment DockingVirtual Screening | Small Molecule ModellingPharmacophore ElucidationLibrary EnumerationLibrary Profiling/Clustering/SamplingConformer Generation/Charges/TautomersMolecular DockingDesign of Synthetic libraries |
News: 30th July 2018. Autotaxin publishes in J.Med.Chem
News: 19th July 2017.Pulmocide Respiratory Syncytial Virus (RSV) Project Project reaches FIH |
||
News: 4th July 2017.Charnwood Molecular teams up with Computational Chemistry Partner, CCR |
||
Charnwood Molecular has signed a collaboration agreement with computational chemistry specialist, CCR, a Structure Based Design Consultancy headed by John King-Underwood.
By partnering with CCR, Charnwood Molecular is able to further extend its offering for effective drug discovery. This partnership will deliver contract services which help chemists design, discover and optimise small molecules against particular project targets. CCR provides the benefits of 25 years of experience in drug discovery gained in big pharma, biotech and consultancy, encompassing many different projects and target classes. Since its conception in 2003, CCR has enabled many of its clients to achieve significant growth and success. CCR will assist Charnwood Molecular in providing the following skills to medicinal chemistry projects:
Commenting on the partnership with Charnwood, John King-Underwood said: “We work with a range of partners to enhance and meet clients’ research efforts. We are delighted to be working with Charnwood Molecular at an exciting time when they are growing and working with more and more small companies needing to access first class discovery chemistry contract services. We all look forward to delivering our partnership to clients across the world.” Dr Robin Wilkes, Director of Business Development at Charnwood Molecular stated: “CCR’s reputation, experience in tackling computational problems and proactive approach makes them the ideal collaborator for the fast-moving medicinal chemistry projects that we are increasingly working on. By adding these services and expertise to the Charnwood Molecular portfolio, we have further broadened our capabilities as a collaborative and enabling company to support drug discovery organisations.”
|
Home |
About |
Publications |
Science |
Contact |